Azalea Therapeutics

Executive Summary

Azalea Therapeutics is a preclinical biopharmaceutical company developing innovative biologic therapies for sight-threatening ophthalmic conditions, primarily age-related macular degeneration (AMD) and diabetic retinopathy. Founded in 2018 and headquartered in Bedford, MA, the company focuses on novel targets that aim to improve upon current standard-of-care treatments, such as anti-VEGF therapies, by offering enhanced durability, efficacy, or patient convenience. With $82 million raised to date, Azalea is well-capitalized for a preclinical-stage firm, enabling it to advance its pipeline toward clinical development. The company's proprietary biologics target key pathways in retinal disease, potentially addressing significant unmet needs in a large and growing patient population. If successful, Azalea's therapies could offer meaningful advantages over existing options, including less frequent dosing or improved visual outcomes. The company remains privately held and has not yet disclosed a specific lead candidate or timeline for entering the clinic, but its substantial funding and experienced team position it for potential IND-enabling studies in the near term. Investors should monitor for preclinical data releases and regulatory milestones as the company transitions toward first-in-human trials.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Candidate70% success
• Q2 2026Preclinical Data Presentation at Major Ophthalmology Conference85% success
• Q4 2026Series C Financing or Partnership Announcement60% success